Physician profile
Bryce Gibson
NPI 1538570569
$3,333.39
in general payments reported to CMS, 2019-2025
35 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.96 · 2020: $26.38 · 2021: $260 · 2022: $492 · 2023: $322 · 2024: $1,091 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $489.06 | 2021-2025 | |
| Pfizer INC. | $475.15 | 2019-2025 | |
| Novo Nordisk INC | $411.46 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $337.35 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Corium, LLC | $257.81 | 2022-2024 | Azstarys |
| Exact Sciences Corporation | $109.93 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $95.87 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.21 | 2023-2024 | Xifaxan |
| Averitas Pharma INC. | $85.32 | 2024 | Qutenza |
| Supernus Pharmaceuticals, INC. | $85.28 | 2021-2022 | |
| Baxter Healthcare | $75.71 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $75.47 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Dexcom, INC. | $74.38 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $68.69 | 2021-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $62.87 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.12 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $50.83 | 2024-2025 | |
| Shield Therapeutics INC | $46.10 | 2025 | |
| Ironshore Pharmaceuticals INC. | $44.26 | 2021-2023 | Jornay Pm |
| Inspire Medical Systems, INC. | $41.46 | 2024-2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $40.11 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $30.59 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $27.73 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $27.57 | 2023 | Auvelity |
| Clarus Therapeutics INC. | $23.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.97 | 2024 | |
| Alkermes, INC. | $19.35 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.20 | 2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $16.12 | 2021 | |
| Hologic Sales and Service, LLC | $14.73 | 2022 | |
| Amarin Pharma, INC. | $14.22 | 2020 | |
| Insulet Corporation | $14.10 | 2024 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $13.99 | 2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.79 | 2023 | |
| Sanofi Pasteur INC. | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.